Equity Details
Price & Market Data
Price: $3.64
Daily Change: +$0.119 / 3.26%
Daily Range: $3.49 - $3.69
Market Cap: $393,619,296
Daily Volume: 1,707,823
Performance Metrics
1 Week: 1.54%
1 Month: 15.08%
3 Months: 72.62%
6 Months: 51.04%
1 Year: 160.8%
YTD: 85.90%
About C4 Therapeutics, Inc. (CCCC)
Detailed report on C4 Therapeutics, Inc. (CCCC). Current price: 3.64, daily change: +$0.119 / 3.26%. Market cap: 393,619,296. Explore all performance metrics.
Company Details
Employees: 104
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
